



INTERNATIONAL CONGRESS OF THE
EGYPTIAN
OPHTHALMOLOGICAL SOCIETY

In collaboration with:



EXTENSIVE EYELID AND EPIBULBAR MASSES: CONSERVATIVE MANAGEMENT

IHAB SAAD OTHMAN, MD, FRCS

PROFESSOR, CAIRO UNIVERSITY

CHAIRMAN, EYEWORLD HOSPITAL

VICE PRESIDENT, MEACO

TFOS AMBASSADOR

IN THE MIDDLE EAST

- Sun exposure stimulates eyelid and ocular surface neoplasia
- Cancer predisposition:
 - Consanguineous marriage: Elevated incidence of xeroderma pigmentosa
 - Systemic cancer, chemotherapy, immunosuppression
- Delay in clinical presentation
- Diagnostic and therapeutic challenges

CASE 1: 58 YOM

CHALAZION → SURGERY X 2SEBACEOUS GLAND CARCINOMA




TUMOR EXCISION, FROZEN SECTION CONTROL



MAJOR RECONSTRUCTION: BRIDGE FLAP







CASE 2:

64 YOM, EXCISION OF UL TARSAL MASS
CONJUNCTIVO-PALPEBRAL MALIGNANCY



IDENTIFY TUMOR EXTENT



TUMERECTOMY -----CRYOTHERAPY



CRYO DOUBLE FREEZE THAW.....BRACHYTHERAPY



1 MONTH18 MONTHS



24 MONTHS



CASE 3: 75 YOF

UL TARSAL MELANOMA, EXTENSIVE PAM



PAM



MELANOMA




TUMERECTOMY



BRACHYTHERAPY



ONE YEAR




4 YEARS



RADIATION TYPES

- Alfa particles: positive electrical charges (helium/proton)
- Beta particles: negative charges
- Gamma rays: no electrons:
 - Gamma rays are similar to x-rays, but gamma rays originate in the atomic nucleus and x-rays from the peripheral electrons.

- The major goal of radiation:
 - Arresting cell mitoses by interfering with DNA synthesis
 - Destroy the reproductive integrity of a neoplasm
- The tissue destruction by ionizing radiation is accomplished by free radicals.
- Teletherapy:
 - Remote distance delivery
- Brachytherapy:
 - Near distance delivery



PLAQUE RADIOTHERAPY:


Isotope	Half-life	Radiation
Co-60	5.26 years	Gamma
I-125	60.2 days	Gamma
Pa-103	17 days	Gamma
Ir-192	74.2 days	Gamma
Au-198	3 days	Gamma
Ru-106	366 days	Beta

CASE 4: 58 YOM , RECURRENT SCC CONJUNCTIVA
NEGLECTED X 2 YEARS



STEREOTACTIC RADIO THERAPY

PHAKO IOL OD




JANUARY 2019




JANUARY 2020







January 2019

January 2020



CASE 5: 76 YOM, RECURRENT ORBITO/CONJUNCTIVAL
MELANOMA
- LNS





36 MONTHS



Nuclear Medicine Dept.
PET/CT Unit




الأطفال - مصر
Children's Cancer Hospital
Foundation - Egypt

IMPRESSION:

PET/CT study for a known case of surgically treated malignant melanoma revealed;

- FDG avid metastatic hepatic, lung and osseous deposits as described.

TWO MONTHS POST BLEOMYCIN






3 MONTHS




4 MONTHS










5 MONTHS



6 MONTHS



15 MONTHS



18 MONTHS



INTRALESIONAL BLEOMYCIN IS EFFECTIVE IN LOCAL CONTROL OF DIFFUSE CONJUNCTIVAL AND ORBITAL MELANOMA


IHAB SAAD OTHMAN, MD, FRCS

PROFESSOR OF OPHTHALMOLOGY, CAIRO UNIVERSITY

DIRECTOR EYEWORLD HOSPITAL, EGYPT

<Disclosures>

- Glycopeptide antibiotic; inhibits DNA, RNA, protein synthesis in G2, M phases
- Pharmacokinetics
 - Half-Life: 2 hr
 - Protein Bound: 1%
- Dose:
 - 15 IU of Bleomycin for six weekly doses




The background is a dark blue gradient with a subtle pattern of white dots. Overlaid on the left side is a large, semi-transparent graphic consisting of several concentric circles and a scale. The scale is a circular arc with numerical markings from 140 to 260 in increments of 10. There are also smaller concentric circles and dashed lines with arrows indicating a clockwise direction.



CASE STUDY

IHAB SAAD OTHMAN, MD, FRCS

PROFESSOR, CAIRO UNIVERSITY
CHAIRMAN, EYEWORLD HOSPITAL

OS 2023/02/16 15:15:41








3 cycles
MMC




40 YOM
FARMER
NASAL PTERYGIUM OD FOR 2 YEARS







CASE STUDY: 60 YOM
RECURRENT OSSN MARCH 2024: REEXCISION/ CRYOTHERAPY,
MMC X 3 CYCLES




CASE STUDY: NOVEMBER 2024: RECURRENCE: BLEOMYCIN




OCTOBER 2024





NOVEMBER 2024




JANUARY 2025




ADDITIONAL SALVAGE BRACHYTHERAPY



6 MONTHS FOLLOW UP- 18 MONTHS




The background features a dark blue gradient with faint, white, concentric circular patterns and a scale-like structure on the left side, resembling a protractor or a circular measurement tool. The scale has markings from 140 to 260 in increments of 10. The main title is centered in large, white, sans-serif capital letters.

HUGE EPIBULBAR MASSES: CONSERVE

IHAB SAAD OTHMAN, MD, FRCS

PROFESSOR, CAIRO UNIVERSITY
CHAIRMAN, EYEWORLD HOSPITAL


70 YOF. OSSN



UBM



EXTENSIVE EPIBULBAR MASS



2 WEEKS





1 YEAR
MMC X 3 CYCLES



ADJUVANT THERAPY: WHY AND WHEN

Pathology	Type	Treatment
Resection edge positive	Dsyplasia or CIN	Observation or topical chemotherapy
Resection edge positive	Invasive SCC	Re-excision
Resection base positive	Localized	Cryotherapy
Resection base positive	Diffuse	Plaque brachytherapy
	Patient prone to recurrence	Immuno-modulation

